10-Q · June 3, 2026
Greenwich LifeSciences reported a net loss of $5.66 million for Q1 2026, an increase from $2.74 million in the same period last year. The company continues to focus on its Phase III clinical trial, Flamingo-01, while…
Earnings analysis · 10-Q
GLSI earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The provided excerpt does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so revenue, margins, EPS, liquidity, and cash-flow trends cannot be assessed. The principal…
Read full summary
The provided excerpt does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so revenue, margins, EPS, liquidity, and cash-flow trends cannot be assessed. The principal disclosed concern is ineffective disclosure controls as of June 30, 2026, driven by multiple accounting, IT, and personnel-process weaknesses. Management is developing a remediation plan, while the filing reports no material changes to the risk factors from the December 31, 2025 Form 10-K.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
No Material Legal Proceedings
The company reported that it is not currently a party to any material legal proceedings and is unaware of any pending or threatened proceeding expected to have a material adverse effect.
What to watch
-
Material Internal-Control Weaknesses
Disclosure controls and procedures were concluded to be ineffective as of June 30, 2026, due to material weaknesses involving segregation of duties, written accounting and IT policies, financial-reporting systems, stock-award software, and employee-expense approvals.
-
Control Remediation Remains Pending
Management stated that no change during the most recent fiscal quarter materially affected, or was reasonably likely to materially affect, internal control over financial reporting; however, a remediation plan is still being developed as of June 30, 2026.
-
No Updated Risk-Factor Disclosure
The filing states there have been no material changes from the risk factors disclosed in the Form 10-K for the year ended December 31, 2025; therefore, no new risk-factor update was identified.
Management's outlook
The provided filing excerpt contains no quantitative revenue or EPS outlook; management’s outlook is not included.
Earlier filings 4
10-K · June 1, 2026
Greenwich LifeSciences reported substantial financial losses and no revenues for the year ended December 31, 2025. The company incurred a net loss of $19.4 million, which continues a trend of increasing net losses,…
10-Q · August 14, 2025
Greenwich LifeSciences reported Q2 2025 net loss of $4,025,278 (EPS $(0.30)), wider than Q2 2024 net loss of $2,606,682 (EPS $(0.20)). Cash declined to $3,125,101 from $4,091,990 at year-end, while operating cash used…
10-Q · May 20, 2025
Greenwich LifeSciences reported a Q1 2025 net loss of $3,258,362 (EPS $(0.25)), worsening from a net loss of $2,473,195 (EPS $(0.19)) in Q1 2024. Cash declined to $2,749,959 as of March 31, 2025 from $4,091,990 at…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.